Restoring active T-cell response could affect both normal healthy cells and tumor cells
Normal immune response
When functioning properly, T cells are activated and can attack tumor cells.
Tumor evasion and T-cell deactivation
Some tumors can evade the immune system through the PD-1 pathway. The PD‑L1 and PD‑L2 ligands on tumors can bind with PD-1 receptors on T cells to inactivate the T cells.
T-cell reactivation with KEYTRUDA
KEYTRUDA binds to the PD-1 receptor and blocks its interaction with PD‑L1 and PD‑L2, which helps restore the immune response. While having an effect on the tumor, this could also affect normal healthy cells.
KEYTRUDA as a Single Agent
KEYTRUDA With Axitinib
Adrenal Insufficiency
Hypophysitis
Thyroid Disorders
Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis